3,148 Shares in Revolution Medicines, Inc. $RVMD Bought by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,148 shares of the company’s stock, valued at approximately $251,000.

Several other institutional investors and hedge funds have also modified their holdings of RVMD. General Atlantic L.P. bought a new stake in shares of Revolution Medicines during the 3rd quarter worth $115,556,000. Norges Bank bought a new stake in shares of Revolution Medicines during the 4th quarter worth $195,568,000. UBS Group AG lifted its position in shares of Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock worth $245,954,000 after buying an additional 1,998,972 shares during the last quarter. Nextech Invest Ltd. lifted its position in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Revolution Medicines during the 2nd quarter worth $44,148,000. 94.34% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Mark A. Goldsmith sold 120,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the completion of the transaction, the insider directly owned 276,698 shares in the company, valued at $41,529,602.82. This trade represents a 30.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is owned by company insiders.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $160.06 on Tuesday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $34.03 billion, a PE ratio of -22.64 and a beta of 1.40. Revolution Medicines, Inc. has a 12 month low of $34.00 and a 12 month high of $166.50. The stock has a 50-day moving average price of $141.98 and a two-hundred day moving average price of $111.27.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the previous year, the company posted ($1.13) earnings per share. Analysts expect that Revolution Medicines, Inc. will post -7.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on RVMD. Jefferies Financial Group began coverage on Revolution Medicines in a research report on Monday, March 16th. They set a “buy” rating for the company. Benchmark restated an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Evercore restated an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Wedbush reiterated an “outperform” rating on shares of Revolution Medicines in a research report on Monday, June 1st. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines currently has an average rating of “Buy” and a consensus target price of $123.72.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.